한글목차

세계의 불임 치료제 및 디바이스 시장 규모는 2034년까지 CAGR 6.2%로 성장할 것으로 예측되고 있습니다.

고액의 치료비 :

체외수정(IVF) 1 사이클의 비용은 시설 및 환자 요구에 따라 따르나, 미국에서는 15,000-30,000달러입니다. 진찰료가 이 비용의 35%를 차지하며, 배 유전자 검사 및 외과적 시술 등 기타 추가 비용이 발생하기 때문에 비용이 더 많이 듭니다. 또한 비용은 시술 횟수에 따라 달라지는데, 그 범위는 1-6회까지 다양해 환자들에게 큰 경제적 부담을 안겨줍니다. 이러한 고가의 치료비는 환자의 사용과 적절한 치료 옵션을 제한하고 시장 성장을 저해합니다. 한편, 특히 미국에서는 보험 적용 여부가 보험 플랜에 따라 달라집니다. 미국에서는 고용주가 불임 치료를 보장하기를 원하는 목소리가 높아지고 있습니다.

지원적이지 않은 정부 규제 :

자금 지원, 보조금, 정책, 보조금, 보험 등 정부 규제는 ART 도입에 큰 영향을 미칩니다. 이러한 지원 제도가 없으면 치료 서비스에 대한 접근성이 제한되기 때문에 이러한 임상 서비스의 도입이 제한될 수밖에 없습니다. 일본에서는 저출산 대책의 일환으로 2022년 4월부터 ART 치료가 건강보험 적용을 받게 됩니다. 그 이전에는 저소득층에 초점을 맞추어 대상 부부만 ART 치료의 일부 보조를 받을 수 있었습니다. 한국이나 대만에서도 ART 치료비 지원과 관련해 비슷한 기준을 적용하고 있습니다. 미국에서는 15개 주에서만 민간 보험사가 불임 치료 비용의 일부 또는 전액을 부담할 수 있도록 법으로 허용하고 있으며, 그 유형은 주마다 다르며, 8개 주에서만 ART에 대한 상환을 허용하고 있습니다. 유럽 대부분의 국가에서는 난자와 정자를 포함한 배우자 기증을 허용하고 있습니다. 정자 기증은 EU 20개국에서 난자 기증은 EU 27개국 중 17개국에서 허용하고 있습니다. 이러한 규제는 ART의 채택을 제한하고 시장 성장에 심각한 장벽이 되고 있습니다.

세계의 불임 치료제 및 디바이스 시장을 조사했으며, 시장 개요, 시장 성장에 대한 영향요인 및 시장 기회의 분석, 법규제 환경, 시장 규모의 추이·예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 리포트 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
• 영향 분석
  • 시장을 촉진하는 요인
  • 시장 억제요인
  • 시장 기회
• 공급망 분석
• 규제 프레임워크
• 신흥 시장과 메가트렌드
• Porter's Five Forces 분석
• PEST 분석

제4장 세계의 불임 치료제 및 디바이스 시장 : 제품별

• 주요 조사 결과
• 시장 매력 지수
• 시장 규모의 추이·예측
• 약제
• 장비
• 배지·소모품
• 부속품
  • 시장 규모의 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제5장 세계의 불임 치료제 및 디바이스 시장 : 시술별

• 주요 조사 결과
• 시장 매력 지수
• 시장 규모의 추이·예측
• 시장 점유율
• ART(보조생식기술)
• 인공수정
• 불임 치료 수술
• 기타
  • 시장 규모의 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제6장 세계의 불임 치료제 및 디바이스 시장 : 환자별

• 주요 조사 결과
• 시장 매력 지수
• 시장 규모의 추이·예측
• 시장 점유율
• 여성
• 남성
  • 시장 규모의 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제7장 세계의 불임 치료제 및 디바이스 시장 : 최종사용자별

• 주요 조사 결과
• 시장 매력 지수
• 시장 규모의 추이·예측
• 시장 점유율
• 불임 치료 센터
• 병원·외과 클리닉
• 크라이오뱅크
• 연구기관
  • 시장 규모의 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제8장 세계의 불임 치료제 및 디바이스 시장 : 지역별

• 주요 조사 결과
• 시장 규모의 추이·예측

제9장 북미의 불임 치료제 및 디바이스 시장 분석

제10장 유럽의 불임 치료제 및 디바이스 시장 분석

제11장 아시아태평양의 불임 치료제 및 디바이스 시장 분석

제12장 라틴아메리카의 불임 치료제 및 디바이스 시장 분석

제13장 중동 및 아프리카의 불임 치료제 및 디바이스 시장 분석

제14장 경쟁 구도

• 기업 순위 분석
• 주요 사업 전략 분석

제15장 기업 개요

• The Cooper Companies, Inc.
• Vitrolife
• Thermo Fisher Scientific
• Hamilton Thorne
• Esco Micro Pte Ltd
• FUJIFILM Irvine Scientific
• The Baker Company
• Merck KGaA
• Ferring BV
• Abbott

제16장 결론·제안

• Visiongain으로부터의 결론
• 시장 참여 기업에 대한 제안

영문목차

The global Infertility Drugs & Devices market is projected to grow at a CAGR of 6.2% by 2034

The Infertility Drugs & Devices Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

High cost of treatment

A single IVF cycle ranges from US$15,000 to US$30,000, depending on the centre and the patient needs. Medications constitute 35% of these charges and other additional costs such as genetic testing of the embryos and surgical procedures that increases the cost further. Also, the costs would also depend on number of cycles conducted that range from 1 to 6, which imposes heavy financial burden on the patients. Such high costs limit the use and appropriate treatment option for the patients restricting market growth. Whereas the insurance coverage especially in the U.S. depends on the coverage plans that the employer has offered. Semen analysis is usually covered. However, major parts of the treatment such as embryo transfer, mini-IVF costs, Full IVF cost, using donor egg costs are not completely covered under insurance. There is a growing demand from employers in the U.S. to also provide fertility treatment coverage.

Unsupportive Government Regulations

Government regulations in the form of funding, grants, policies, subsidies, insurance greatly impact the adoption of ART procedures. Lack of these support systems the access to treatment services is restricted and hence leads to limited adoption of these clinical services. For instance, in Japan, ART treatments were initiated to be covered under health insurance since April 2022 as a move to deal with low fertility rates. Prior to this, only eligible couples received partial subsidies for ART treatment due to focus on lower-income citizens in Japan. Similar norms were set up for ART subsidies in Korea and Taiwan. In the U.S. , only 15 states have authorized legislation to private insurers to cover partial or full costs of infertility treatments, however, type of coverage varies by state, with only 8 states authorizing reimbursement for ART. Most European countries allow gametes donation that includes eggs and sperms. Sperm donation is allowed in 20 EU states while Egg donation is permitted in 17 states of the total 27 EU states. These regulations limit the adoption of ART and hence act as a critical barrier in market growth.

What Questions Should You Ask before Buying a Market Research Report?

How is the Infertility Drugs & Devices market evolving?

What is driving and restraining the Infertility Drugs & Devices market?

How will each Infertility Drugs & Devices submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Infertility Drugs & Devices submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Infertility Drugs & Devices markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Infertility Drugs & Devices projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Infertility Drugs & Devices projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Infertility Drugs & Devices market?

Where is the Infertility Drugs & Devices market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Infertility Drugs & Devices market today, and over the next 10 years:

Our 351-page report provides 156 tables and 245 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Infertility Drugs & Devices prices and recent developments.

Segments Covered in the Report

Product

Drugs

Gonadotropins

Aromatase Inhibitors

Selective Estrogen Receptor Modulators (SERMs)

Dopamine Agonists

Other drug classes

Equipment

Microscopes

Imaging Systems

Sperm Analyzer Systems

Ovum Aspiration Pumps

Micromanipulator Systems

Incubators

Gas Analyzers

Laser Systems

Cryosystems

Sperm Separation Devices

Media & Consumables

Accessories

Procedure

Assisted Reproductive Technology

IVF

Intracytoplasmic Sperm Injection

Surrogacy

Artificial Insemination

Intrauterine

Intracervical

Intratubal

Fertility Surgeries

Laparoscopy

Hysteroscopy

Varicocelectomy

Laparotomy

Tubal Ligation Reversal

Microsurgical Reconstruction

Other Infertility Treatment Procedures

Patient

Female

Male

End-Use

Fertility Centers

Hospitals & Surgical Clinics

Cryobanks

Research Institutes

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 16 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Infertility Drugs & Devices Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

Abbott Laboratories

Esco Micro Pte Ltd

Ferring BV

FUJIFILM Irvine Scientific

Hamilton Thorne

Merck KGaA

The Baker Company

The Cooper Companies, Inc.

Thermo Fisher Scientific

Vitrolife

Overall world revenue for Infertility Drugs & Devices Market, 2024 to 2034 in terms of value the market will surpass US$5.9 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Infertility Drugs & Devices Market, 2024 to 2034 report help you?

In summary, our 350+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Infertility Drugs & Devices Market, 2024 to 2034 Market, with forecasts for product, procedure, patient, end-use, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 16 key national markets - See forecasts for the Infertility Drugs & Devices Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, U.K., Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the Infertility Drugs & Devices Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Infertility Drugs & Devices Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Infertility Drugs & Devices Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report Include:
• 1.6 Who is This Report For?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
• 3.3 Impact Analysis
  • 3.3.1 Market Driving Factors
  • 3.3.2 Market Restraining Factors
  • 3.3.3 Market Opportunities
• 3.4 Supply Chain Analysis
• 3.5 Regulatory Framework
• 3.6 Emerging Markets and Megatrends
• 3.7 Porter's Five Forces Analysis
  • 3.7.1 Supplier Power
  • 3.7.2 Buyer Power
  • 3.7.3 Competitive Rivalry
  • 3.7.4 Threat of Substitutes
  • 3.7.5 Threat of New Entrants
• 3.8 PEST Analysis

4 Global Infertility Drugs & Devices Market Analysis by Product

• 4.1 Key Findings
• 4.2 Product Segment: Market Attractiveness Index
• 4.3 Infertility Drugs & Devices Market Size Estimation and Forecast by Product
• 4.4 Drugs
  • 4.4.1 Drugs Market Forecast by Region, 2024-2034 (US$ Mn)
  • 4.4.2 Drugs Market Share by Region, 2024 and 2034 (%)
  • 4.4.3 Drugs Market Forecast by Type, 2024-2034 (US$ Mn)
  • 4.4.4 Drugs Market Share by Type, 2024 and 2034 (%)
• 4.5 Equipment
  • 4.5.1 Equipment Market Forecast by Region, 2024-2034 (US$ Mn)
  • 4.5.2 Equipment Market Share by Region, 2024 and 2034 (%)
  • 4.5.3 Equipment Market Forecast by Type, 2024-2034 (US$ Mn)
  • 4.5.4 Equipment Market Share by Type, 2024 and 2034 (%)
• 4.6 Media & Consumables
  • 4.6.1 Media & Consumables Market Forecast, 2024-2034 (US$ Mn)
  • 4.6.2 Media & Consumables Market Share by Region, 2024 and 2034 (%)
• 4.7 Accessories
  • 4.7.1 Accessories Market Forecast by Region, 2024-2034 (US$ Mn)
  • 4.7.2 Accessories Market Share by Region, 2024 and 2034 (%)

5 Infertility Drugs & Devices Market Analysis by Procedure

• 5.1 Key Findings
• 5.2 Procedure Segment: Market Attractiveness Index
• 5.3 Infertility Drugs & Devices Market Size Estimation and Forecast by Procedure
• 5.4 Infertility Drugs & Devices Market Share by Procedure, 2024 & 2034
• 5.5 Assisted Reproductive Technology
  • 5.5.1 Assisted Reproductive Technology Market Forecast by Region, 2024-2034 (US$ Mn)
  • 5.5.2 Assisted Reproductive Technology Market Share by Region, 2024 and 2034 (%)
  • 5.5.3 Assisted Reproductive Technology Market Forecast by Type, 2024-2034 (US$ Mn)
  • 5.5.4 Assisted Reproductive Technology Market Share by Type, 2024 and 2034 (%)
• 5.6 Artificial Insemination
  • 5.6.1 Artificial Insemination Market Forecast, 2024-2034 (US$ Mn)
  • 5.6.2 Artificial Insemination Market Share by Region, 2024 and 2034 (%)
  • 5.6.3 Artificial Insemination Market Forecast by Type, 2024-2034 (US$ Mn)
  • 5.6.4 Artificial Insemination Market Share by Type, 2024 and 2034 (%)
• 5.7 Fertility Surgeries
  • 5.7.1 Fertility Surgeries Market Forecast by Region, 2024-2034 (US$ Mn)
  • 5.7.2 Fertility Surgeries Market Share by Region, 2024 and 2034 (%)
  • 5.7.3 Fertility Surgeries Market Forecast by Type, 2024-2034 (US$ Mn)
  • 5.7.4 Fertility Surgeries Market Share by Type, 2024 and 2034 (%)
• 5.8 Other Infertility Treatment Procedures
  • 5.8.1 Other Infertility Treatment Procedures Market Forecast by Region, 2024-2034 (US$ Mn)
  • 5.8.2 Other Infertility Treatment Procedures Market Share by Region, 2024 and 2034 (%)

6 Infertility Drugs & Devices Market Analysis by Patient

• 6.1 Key Findings
• 6.2 Patient Segment: Market Attractiveness Index
• 6.3 Infertility Drugs & Devices Market Size Estimation and Forecast by Patient
• 6.4 Infertility Drugs & Devices Market Share by Patient, 2024, 2029, 2034
• 6.5 Female
  • 6.5.1 Female Market Forecast by Region, 2024-2034 (US$ Mn)
  • 6.5.2 Female Market Share by Region, 2024 and 2034 (%)
• 6.6 Male
  • 6.6.1 Male Market Forecast by Region, 2024-2034 (US$ Mn)
  • 6.6.2 Male Market Share by Region, 2024 and 2034 (%)

7 Infertility Drugs & Devices Market Analysis by End-use

• 7.1 Key Findings
• 7.2 End-use Segment: Market Attractiveness Index
• 7.3 Infertility Drugs & Devices Market Size Estimation and Forecast by End-use
• 7.4 Infertility Drugs & Devices Market Share by End-use, 2024, 2029, 2034
• 7.5 Fertility Centers
  • 7.5.1 Fertility Centers Market Forecast by Region, 2024-2034 (US$ Mn)
  • 7.5.2 Fertility Centers Market Share by Region, 2024 and 2034 (%)
• 7.6 Hospitals & Surgical Clinics
  • 7.6.1 Hospitals & Surgical Clinics Market Forecast by Region, 2024-2034 (US$ Mn)
  • 7.6.2 Hospitals & Surgical Clinics Market Share by Region, 2024 and 2034 (%)
• 7.7 Cryobanks
  • 7.7.1 Cryobanks Market Forecast by Region, 2024-2034 (US$ Mn)
  • 7.7.2 Cryobanks Market Share by Region, 2024 and 2034 (%)
• 7.8 Research Institutes
  • 7.8.1 Research Institutes Market Forecast by Region, 2024-2034 (US$ Mn)
  • 7.8.2 Research Institutes Market Share by Region, 2024 and 2034 (%)

8 Infertility Drugs & Devices Market Analysis by Region

• 8.1 Key Findings
• 8.2 Regional Market Size Estimation and Forecast

9 North America Infertility Drugs & Devices Market Analysis

• 9.1 Key Findings
• 9.2 North America Infertility Drugs & Devices Market Attractiveness Index
• 9.3 North America Infertility Drugs & Devices Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 9.4 North America Infertility Drugs & Devices Market Size Estimation and Forecast by Country
• 9.5 North America Infertility Drugs & Devices Market Size Estimation and Forecast by Product
• 9.6 North America Infertility Drugs & Devices Market Size Estimation and Forecast by Drugs
• 9.7 North America Infertility Drugs & Devices Market Size Estimation and Forecast by Equipment
• 9.8 North America Infertility Drugs & Devices Market Size Estimation and Forecast by Procedure
• 9.9 North America Infertility Drugs & Devices Market Size Estimation and Forecast by Patient
• 9.10 North America Infertility Drugs & Devices Market Size Estimation and Forecast by End-users
• 9.11 U.S.
  • 9.11.1 U.S. Infertility Drugs & Devices Market by Product
• 9.12 Canada
  • 9.12.1 Canada Infertility Drugs & Devices Market by Product

10 Europe Infertility Drugs & Devices Market Analysis

• 10.1 Key Findings
• 10.2 Europe Infertility Drugs & Devices Market Attractiveness Index
• 10.3 Europe Infertility Drugs & Devices Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 10.4 Europe Infertility Drugs & Devices Market Size Estimation and Forecast by Country
• 10.5 Europe Infertility Drugs & Devices Market Size Estimation and Forecast by Product
• 10.6 Europe Infertility Drugs & Devices Market Size Estimation and Forecast by Drugs
• 10.7 Europe Infertility Drugs & Devices Market Size Estimation and Forecast by Equipment
• 10.8 Europe Infertility Drugs & Devices Market Size Estimation and Forecast by Procedure
• 10.9 Europe Infertility Drugs & Devices Market Size Estimation and Forecast by Patient
• 10.10 Europe Infertility Drugs & Devices Market Size Estimation and Forecast by End-use
• 10.11 Germany
  • 10.11.1 Germany Infertility Drugs & Devices Market by Product
• 10.12 U.K.
  • 10.12.1 U.K. Infertility Drugs & Devices Market by Product
• 10.13 France
  • 10.13.1 France Infertility Drugs & Devices Market by Product
• 10.14 Italy
  • 10.14.1 Italy Infertility Drugs & Devices Market by Product
• 10.15 Spain
  • 10.15.1 Spain Infertility Drugs & Devices Market by Product
• 10.16 Rest of Europe
  • 10.16.1 Rest of Europe Infertility Drugs & Devices Market by Product

11 Asia Pacific Infertility Drugs & Devices Market Analysis

• 11.1 Key Findings
• 11.2 Asia Pacific Infertility Drugs & Devices Market Attractiveness Index
• 11.3 Asia Pacific Infertility Drugs & Devices Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 11.4 Asia Pacific Infertility Drugs & Devices Market Size Estimation and Forecast by Country
• 11.5 Asia Pacific Infertility Drugs & Devices Market Size Estimation and Forecast by Product
• 11.6 Asia Pacific Infertility Drugs & Devices Market Size Estimation and Forecast by Drugs
• 11.7 Asia Pacific Infertility Drugs & Devices Market Size Estimation and Forecast by Equipment
• 11.8 Asia-Pacific Infertility Drugs & Devices Market Size Estimation and Forecast by Procedure
• 11.9 Asia Pacific Infertility Drugs & Devices Market Size Estimation and Forecast by Patient
• 11.10 Asia Pacific Infertility Drugs & Devices Market Size Estimation and Forecast by End-use
• 11.11 Japan
  • 11.11.1 Japan Infertility Drugs & Devices Market by Product
• 11.12 China
  • 11.12.1 China Infertility Drugs & Devices Market by Product
• 11.13 India
  • 11.13.1 India Infertility Drugs & Devices Market by Product
• 11.14 South Korea
  • 11.14.1 South Korea Infertility Drugs & Devices Market by Product
• 11.15 Australia
  • 11.15.1 Australia Infertility Drugs & Devices Market by Product
• 11.16 Rest of APAC
  • 11.16.1 Rest of APAC Infertility Drugs & Devices Market by Product

12 Latin America Infertility Drugs & Devices Market Analysis

• 12.1 Key Findings
• 12.2 Latin America Infertility Drugs & Devices Market Attractiveness Index
• 12.3 Latin America Infertility Drugs & Devices Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 12.4 Latin America Infertility Drugs & Devices Market Size Estimation and Forecast by Country
• 12.5 Latin America Infertility Drugs & Devices Market Size Estimation and Forecast by Product
• 12.6 Latin America Infertility Drugs & Devices Market Size Estimation and Forecast by Drugs
• 12.7 Latin America Infertility Drugs & Devices Market Size Estimation and Forecast by Equipment
• 12.8 Latin America Infertility Drugs & Devices Market Size Estimation and Forecast by Procedure
• 12.9 Latin America Infertility Drugs & Devices Market Size Estimation and Forecast by Patient
• 12.10 Latin America Infertility Drugs & Devices Market Size Estimation and Forecast by End-use

12.11Brazil

• 12.11.1 Brazil Infertility Drugs & Devices Market by Product
• 12.12 Mexico
  • 12.12.1 Mexico Infertility Drugs & Devices Market by Product
• 12.13 Rest of Latin America
  • 12.13.1 Rest of LATAM Infertility Drugs & Devices Market by Product

13 MEA Infertility Drugs & Devices Market Analysis

• 13.1 Key Findings
• 13.2 MEA Infertility Drugs & Devices Market Attractiveness Index
• 13.3 MEA Infertility Drugs & Devices Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 13.4 MEA Infertility Drugs & Devices Market Size Estimation and Forecast by Country
• 13.5 MEA Infertility Drugs & Devices Market Size Estimation and Forecast by Product
• 13.6 MEA Infertility Drugs & Devices Market Size Estimation and Forecast by Drugs
• 13.7 MEA Infertility Drugs & Devices Market Size Estimation and Forecast by Equipment
• 13.8 MEA Infertility Drugs & Devices Market Size Estimation and Forecast by Procedure
• 13.9 MEA Infertility Drugs & Devices Market Size Estimation and Forecast by Patient
• 13.10 MEA Infertility Drugs & Devices Market Size Estimation and Forecast by End-use
• 13.11 South Africa
  • 13.11.1 South Africa Infertility Drugs & Devices Market by Product
• 13.12 GCC
  • 13.12.1 GCC Infertility Drugs & Devices Market by Product
• 13.13 Rest of MEA
  • 13.13.1 Rest of MEA Infertility Drugs & Devices Market by Product

14 Competitive Landscape

• 14.1 Company Ranking Analysis
• 14.2 Key Business Strategy Analysis

15 Company Profiles

• 15.1 The Cooper Companies, Inc.
  • 15.1.1 Company Snapshot
  • 15.1.2 Company Overview
  • 15.1.3 Financial Analysis
  • 15.1.4 Product Benchmarking
  • 15.1.5 Strategic Outlook
  • 15.1.6 SWOT Analysis
• 15.2 Vitrolife
  • 15.2.1 Company Snapshot
  • 15.2.2 Company Overview
  • 15.2.3 Financial Analysis
  • 15.2.4 Product Benchmarking
  • 15.2.5 Strategic Outlook
• 15.3 Thermo Fisher Scientific
  • 15.3.1 Company Snapshot
  • 15.3.2 Company Overview
  • 15.3.3 Financial Analysis
  • 15.3.4 Product Benchmarking
  • 15.3.5 Strategic Outlook
• 15.4 Hamilton Thorne
  • 15.4.1 Company Snapshot
  • 15.4.2 Company Overview
  • 15.4.3 Financial Analysis
  • 15.4.4 Product Benchmarking
  • 15.4.5 Strategic Outlook
• 15.5 Esco Micro Pte Ltd
  • 15.5.1 Company Snapshot
  • 15.5.2 Company Overview
  • 15.5.3 Product Benchmarking
  • 15.5.4 Strategic Outlook
• 15.6 FUJIFILM Irvine Scientific
  • 15.6.1 Company Snapshot
  • 15.6.2 Company Overview
  • 15.6.3 Financial Analysis
  • 15.6.4 Product Benchmarking
  • 15.6.5 Strategic Outlook
  • 15.6.6 SWOT Analysis
• 15.7 The Baker Company
  • 15.7.1 Company Snapshot
  • 15.7.2 Company Overview
  • 15.7.3 Product Benchmarking
  • 15.7.4 Strategic Outlook
• 15.8 Merck KGaA
  • 15.8.1 Company Snapshot
  • 15.8.2 Company Overview
  • 15.8.3 Financial Analysis
  • 15.8.4 Product Benchmarking
  • 15.8.5 Strategic Outlook
• 15.9 Ferring BV
  • 15.9.1 Company Snapshot
  • 15.9.2 Company Overview
  • 15.9.3 Product Benchmarking
  • 15.9.4 Strategic Outlook
  • 15.9.5 SWOT Analysis
• 15.10 Abbott
  • 15.10.1 Company Snapshot
  • 15.10.2 Company Overview
  • 15.10.3 Financial Analysis
  • 15.10.4 Product Benchmarking

16 Conclusion and Recommendations

• 16.1 Concluding Remarks from Visiongain
• 16.2 Recommendations for Market Players